[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BeiGene\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":157},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,75,112,135],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100421694",false,"NCT04771130","A Study of BGB-11417 in Participants With Myeloid Malignancies","A Phase 1b\u002F2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies","Key Inclusion Criteria:\n\n1. Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:\n\n   * AML, nonacute promyelocytic leukemia\n   * MDS\n   * MDS\u002FMPN\n2. Eastern Cooperative Oncology Group performance status of 0 to 2.\n3. Adequate organ function defined as:\n\n   * Creatinine clearance ≥ 50 milliliters\u002Fminute (mL\u002Fmin) (or between 30 and 49 mL\u002Fmin in unfit AML cohort)\n   * Adequate liver function\n4. Life expectancy of \\> 12 weeks.\n5. Ability to comply with the requirements of the study.\n\nKey Exclusion Criteria:\n\n1. A diagnosis of acute promyelocytic leukemia.\n2. History of prior malignancy, with the exception of either a history of MDS or MDS\u002FMPN that has transformed to AML, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer)\n3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.\n4. Prior therapy with a B-cell lymphoma-2 inhibitor\n5. Known central nervous system involvement by leukemia.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":18,"type":19},260,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS\u002Fmyeloproliferative neoplasm (MPN) .",[26,27,28],"Acute Myeloid Leukemia","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm",[30,31,32,33,34,35],"BGB-11417","Azacitidine","Posaconazole","AML","MDS","MDS\u002FMPN","RECRUITING","2026-04-21",{"date":39,"type":40},"2026-04-23","ACTUAL",{"date":42,"type":40},"2021-05-24",{"date":44,"type":19},"2028-02-08",{"name":46,"class":47},"BeiGene","INDUSTRY",46,{"id":50,"slug":51,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100342305","phase-2-tislelizumab-anti-programmed-cell-death-protein-1-pd-1-antibody-in-msi-h-or-dmmr-solid-tumors-100342305","NCT03736889","Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors","Key Inclusion Criteria:\n\n1. Having histological confirmed diagnosis of malignancy\n2. Having locally advanced unresectable or metastatic solid tumors with MSI-H or dMMR\n3. Having received prior cancer therapy regimen(s) for advanced disease.\n4. At least 1 measurable lesion as defined per RECIST Version (v) 1.1\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1\n6. Adequate organ function\n\nKey Exclusion Criteria:\n\n1. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\n2. Active leptomeningeal disease or uncontrolled brain metastasis.\n3. Clinically significant pleural effusion, pericardial effusion or ascites\n4. Active autoimmune diseases or history of autoimmune diseases that may relapse\n5. Any active malignancy\n6. Any condition that required systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug\n7. Having a history of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, acute lung diseases, or uncontrolled systemic diseases (including but not limited to diabetes, hypertension, etc.)\n8. Participants with uncontrolled diabetes or uncontrolled electrolyte disorders despite standard medical management\n9. Having severe chronic or active infections\n10. A known history of human immunodeficiency virus infection\n11. Child - Pugh B or greater cirrhosis\n12. Any major surgical procedure ≤ 28 days before the first dose of study drug\n13. Prior allogeneic stem cell transplantation or organ transplantation\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":57,"type":19},200,[23],"In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).",[61],"MSI-H\u002FdMMR Solid Tumors",[63,64,65],"MSI-H\u002FdMMR","Solid tumors","PD-1","2026-04-20",{"date":68,"type":40},"2026-04-22",{"date":70,"type":40},"2018-09-19",{"date":72,"type":19},"2027-09",{"name":46,"class":47},29,{"id":76,"slug":77,"hasResults":10,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":84,"briefSummary":85,"conditions":86,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":74},"100461905","phase-1-treatment-of-chinese-participants-with-b-cell-malignancies-with-bgb-16673-a-bruton-tyrosine-kinase-targeted-protein-degrader-100461905","NCT05294731","Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","A Phase 1\u002F2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies","Key Inclusion Criteria\n\n1. Provision of signed and dated written informed consent prior to any study\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2\n3. Adequate organ function of coagulation function, liver function, renal function and pancreatic function and measure disease per disease-specific response criteria\n4. Phase 1: Confirmed diagnosis of R\u002FR Marginal Zone Lymphoma (MZL), Follicular Lymphoma (grade 1-3a), Waldenström Macroglobulinemia (WM), non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), Richter's transformation to DLBCL, MCL, or CLL\u002FSLL\n5. Phase 2: Confirmed diagnosis of MCL, or CLL\u002FSLL\n6. Highly effective method of birth control during study treatment period, and for at least 90 days after the last dose of the study drug\n\nKey Exclusion Criteria\n\n1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer\n2. Require ongoing systemic treatment for any other malignancy or systemic corticosteroid treatment\n3. Receiving treatment with a strong CYP3A inhibitor or inducer ≤ 14 days before the first dose of BGB-16673, or proton-pump inhibitors ≤ 5 days before the first dose of BGB-16673.\n4. Current or history of central nervous involvement\n5. Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":83,"type":19},146,[22,23],"This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts",[87,88,89,90,91,92,93,94,95],"B-cell Malignancy","Non-Hodgkin Lymphoma","Mantle Cell Lymphoma","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Waldenström Macroglobulinemia","Marginal Zone Lymphoma","Follicular Lymphoma","DLBCL Unclassifiable","Richter's Transformation",[87,97,98,99,95,100,101,102,103],"MZL","FL","DLBCL","CDAC","BTK","degrader","BGB-16673","2026-04-14",{"date":106,"type":40},"2026-04-17",{"date":108,"type":40},"2022-05-06",{"date":110,"type":19},"2029-01-31",{"name":46,"class":47},{"id":113,"slug":114,"hasResults":10,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100488437","observational-study-evaluating-the-efficacy-and-safety-of-zanubrutinib-in-participants-with-waldenstrm-macroglobulinemia-100488437","NCT05640102","Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia","Inclusion Criteria:\n\n* Clinical and definitive histologic diagnosis of WM\n* Measurable disease, as defined by a serum immunoglobulin M (IgM) level \\> 0.5 g\u002FdL at the time of zanubrutinib initiation\n* Started treatment with zanubrutinib, has been treated with zanubrutinib, or is planned to be prescribed zanubrutinib for the treatment of WM\n* Bone marrow specimens with central MYD88 test results of:\n\n  1. Cohort 1: MYD88 L265P mutation; enrollment of TN participants will be stopped in each racial and ethnic participant group when the required numbers of participants in the group are met\n  2. Cohort 2: non-L265P MYD88 mutation(s) and MYD88WT\n\nExclusion Criteria:\n\n* Evidence of disease transformation before the first dose of zanubrutinib\n* Evidence of other non-Hodgkin Lymphoma (NHL) subtypes\n* Prior or concurrent active malignancy ≤ 2 years before the first dose of zanubrutinib, except for malignancies that, in the investigator's opinion, will not obscure the interpretation of safety or efficacy results\n* Concurrent participation in another therapeutic clinical study while receiving zanubrutinib, although the participant may be eligible depending on the status of the interventional study after discussion with the Medical Monitor or designee on an individual basis",{"count":120,"type":19},111,"5 Years","OBSERVATIONAL","This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.",[125],"Waldenstrom Macroglobulinemia","2026-03-03",{"date":128,"type":40},"2026-03-04",{"date":130,"type":40},"2023-03-03",{"date":132,"type":19},"2027-12",{"name":46,"class":47},8,{"id":136,"slug":137,"hasResults":10,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":144,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":134},"100605960","phase-4-a-study-to-evaluate-the-efficacy-and-safety-of-zanubrutinib-in-chinese-adults-with-treatment-naive-waldenstrm-macroglobulinemia-100605960","NCT07169331","A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia","A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia","Inclusion Criteria:\n\n* Clinical and definitive histologic diagnosis of WM. Participant must be treatment-naive.\n* Participant must meet at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's macroglobulinemia (IWWM).\n* Participant must have measurable disease, as defined by serum immunoglobulin M (IgM) level \\> 0.5 g\u002FdL.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Participants must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study treatment:\n\n  1. Participants must not have required blood transfusion or growth factor support ≤ 7 days before sample collection at screening for the following:\n\n     * Absolute neutrophil count (ANC) ≥ 0.75 x 10\\^9\u002FL.\n     * Platelets ≥ 50 x 10\\^9\u002FL.\n  2. Creatinine clearance of ≥ 30 ml\u002Fmin as estimated by the Cockcroft-Gault formula.\n  3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN).\n  4. Serum total bilirubin ≤ 2 x ULN (total bilirubin must be \\\u003C 3 x ULN for participants with Gilbert syndrome).\n* Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for at least 1 month after the last dose of zanubrutinib. They must also have a negative urine or serum pregnancy test result ≤ 7 days before the first dose of study treatment.\n\nExclusion Criteria:\n\n* Evidence of disease transformation at the time of study entry.\n* Central nervous system (CNS) involvement by WM. Patients with a history of CNS involvement must undergo magnetic resonance imaging (MRI) and cerebrospinal fluid cytology studies to document no evidence of CNS disease prior to study entry.\n* Evidence of disease transformation at the time of study entry.\n* Participants with any of the following cardiovascular risk factors:\n\n  1. Active cardiac ischemia (eg, cardiac chest pain) ≤ 28 days before first dose of study drug.\n  2. Any history of acute myocardial infarction ≤ 6 months before the first dose of study drug.\n  3. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 7)≤ 6 months before the first dose of study drug.\n  4. Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before the first dose of study drug.\n  5. Active, clinically significant second-degree atrioventricular block Mobitz II, or third degree atrioventricular block.\n  6. Any history of cerebrovascular accident ≤ 6 months before the first dose of study drug.\n  7. Uncontrolled hypertension that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug.\n  8. Any episode of syncope or seizure ≤ 28 days before first dose of study drug.\n* At the time of study entry, participants taking warfarin or other vitamin K antagonists.\n* Participants requiring ongoing therapy with strong or moderate cytochrome CYP3A inducers\n* Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 4 weeks, or antibody-based therapy within 4 weeks before the start of study drug.\n* Major surgical procedure within 4 weeks before the start of study treatment (bone marrow aspirate and biopsy procedures are not considered major surgical procedures).\n\nNote: Other protocol defined criteria may apply",{"count":143,"type":19},18,[145],"PHASE4","The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.",[148],"Waldenström's Macroglobulinemia","2025-12-15",{"date":151,"type":40},"2025-12-19",{"date":153,"type":40},"2025-10-17",{"date":155,"type":19},"2028-10-31",{"name":46,"class":47},""]